Clinical trial
Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or…
NCT00313053 · Clare Twist, Other · Terminated
Key facts
| NCT number | NCT00313053 |
|---|---|
| Title | Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia |
| Official title | A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Pediatric Patients With Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia |
| Lead sponsor | Clare Twist, Other |
| Collaborators | National Institutes of Health (NIH) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Acute, Acute Lymphoid Leukemia (ALL) |
| Intervention type | Drug |
| Interventions | Human mAb 216, Vincristine |
| Enrollment | 4 |
| Start date | Sep 1, 2004 |
| Primary completion | Apr 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Apr 11, 2006 |
| Last update posted | Jun 3, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: